Ibrutinib CAS 936563-96-1 Ịdị ọcha> 99.5% (HPLC) API

Nkọwa dị mkpirikpi:

Aha Chemical: Ibrutinib

Nọmba: 936563-96-1

Dị ọcha:> 99.5% (HPLC)

Ọdịdị: White ka Gbanyụọ-White Crystal Powder

Ibrutinib bụ ihe mgbochi BTK eji agwọ ọrịa leukemia na-adịghị ala ala (CLL) na Mantle Cell Lymphoma (MCL)

Kpọtụrụ: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Zitere anyị email

Nkọwa ngwaahịa

Ngwaahịa ndị emetụtara

Mkpado ngwaahịa

Nkọwa:

Ndị etiti metụtara Ibrutinib:
(S) -1-Boc-3-Hydroxypiperidine CAS 143900-44-1
4-Phenoxyphenylboronic Acid CAS 51067-38-0
Ibrutinib Intermediate N-2 CAS 330786-24-8
Ibrutinib Intermediate N-3 CAS 330792-70-6
Ibrutinib CAS 936563-96-1

Njirimara kemịkalụ:

Aha Chemical	Ibrutinib
Ụdị okwu	1-[(3R) -3-[4-Amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-1-yl] -1-piperidinyl]-2-propen-1- otu;PCI-32765
Nọmba CAS	936563-96-1
Ọnọdụ Ahịa	N'ọkwa, Mpụta Ihe ruru Tọn
Usoro ihe omimi	C25H24N6O2
Ibu molekụla	440.50
Ụdị	Ruifu Chemical

Nkọwapụta:

Ihe	Nkọwapụta
Ọdịdị	Ntụ ntụ kristal na-acha ọcha ruo na-acha ọcha
njirimara	IR;HPLC
Ọnwụ na ihicha	<0.50%
Ihe fọdụrụ na mgbanye	≤0.10%
Ọla dị arọ (dị ka Pb)	≤20ppm
Ọdịghị ọcha ọ bụla	≤0.20%
Mgbakọta adịghị ọcha	<0.50%
Ụzọ ịdị ọcha / nyocha	> 99.5% (HPLC)
Nlele ọkọlọtọ	Standardkpụrụ ụlọ ọrụ
Ojiji	API

Ngwungwu & Nchekwa:

ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ.

Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri.

Uru:

Ajụjụ:

Ngwa:

Ibrutinib (CAS: 936563-96-1) bụ onye na-egbochi Bruton tyrosine kinase (BTK) maka ọgwụgwọ ọrịa leukemia lymphocytic na-adịghị ala ala (CLL) na lymphoma mantle cell (MCL).Ma MCL na CLL bụ nke B-cell na-abụghị Hodgkin's lymphoma, nke na-agbaji ma na-enwe ike ịlaghachi azụ.Chemoimmunotherapy nke a na-ejikarị eme ihe abụghị ezubere iche, yana mmeghachi omume ọjọọ nke ọkwa 3 ma ọ bụ 4 na-emekarị.Ibrutinib nwere ike ijikọ na BTK, nke dị mkpa maka nguzobe, dị iche iche, nkwurịta okwu na nlanarị nke B lymphocytes, na irreversibly na-egbochi ọrụ nke BTK, n'ụzọ dị irè na-egbochi mmụba na nlanarị nke mkpụrụ ndụ tumo.Tụkwasị na nke ahụ, a na-etinye ya ngwa ngwa mgbe nchịkwa ọnụ gasịrị, a na-enweta ntinye uche plasma kachasị 1 ~ 2h, na mmeghachi omume ọjọọ bụ ọkwa 1 ma ọ bụ 2, nke ga-aghọ nhọrọ ọhụrụ maka ọgwụgwọ CLL na MCL.Na November 13, 2013, US FDA iji mee ka ụlọ ọrụ Johnson & Johnson kwadoro na United States Imbruvica (aha a na-ahụkarị: Ibrutinib) maka ọgwụgwọ nke lymphoma mantle cell (MCL).Ibrutinib, bụ FDA nyere ọkwa ọgwụgwọ ọganihu na February 2013 wee kwado ya maka MCL na Nọvemba 13, 2013 na CLL na February 12, 2014, n'otu n'otu.